Director Hoffman Buys $5M of Annovis Offering — 5M Shares Plus 5M Warrants at $1.00
ANVS sits 43% above its 52-week low of $0.616 on elevated volume (5.7× avg).
Summary
Director Michael B. Hoffman bought 5,000,000 shares and 5,000,000 warrants at a combined $1.00 per unit, $5 million total, in Annovis's just-priced offering. His direct stake rose to 8,364,883 shares.
Key Events · Ownership and Investor Activity · ANVS
-
Director Buys $5M in Offering
Michael B. Hoffman acquired 5,000,000 shares and 5,000,000 warrants for a combined $1.00 per unit, $5,000,000 total, on 2026-11-06.
-
Stake Rises to 8.36M Shares
Post-transaction direct holdings are 8,364,883 shares, plus 223,357 shares held indirectly through the 2024 Hoffman Family Trust.
-
Warrants Strike at $1.00
The 5,000,000 warrants carry a $1.00 exercise price and expire 2031-11-06, so they pay off only above the offering price.
-
Follows Offering and Share Authorization
Comes one day after the $21.0M offering priced on 2026-11-05 and the same week stockholders approved doubling authorized shares to 140 million on 2026-11-04.
Analysis · ANVS · Life Sciences
A board member put $5 million of his own money into the offering Annovis priced on November 5, taking 5,000,000 shares and 5,000,000 warrants at a combined $1.00 per unit. That is real cash, not an option exercise, and it is large next to a company with a roughly $36 million market value. The purchase also lands the day after stockholders approved doubling authorized shares to 140 million, so the raise it funds is the same capital that keeps a going-concern-flagged balance sheet alive. The warrants carry a $1.00 strike and expire in 2031, so his economics improve only if the stock climbs above the offering price.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $0.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.1M. The 52-week trading range was $0.62 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.